Condition

Myeloid Malignancy clinical trials and research

• 14Clinical trials
• 4NIH research projects
• 4Countries

Newest Myeloid Malignancy clinical trials

All recruiting trials (14)

• BG-75202 alone or with other drugs in myeloid malignancies

  This study tests BG-75202, a KAT6A/B inhibitor, alone and with other agents to see if it is safe and potentially helpful for adults with myeloid malignancies.

  Recruiting at 17 sites Phase 1 BeOne Medicines · Concord, New South Wales and 16 other locations · NCT07619287

• RSK1 Inhibitor PMD-026 in myeloid malignancies

  A first-in-human test of PMD-026, an oral drug that blocks RSK1, to see if it is safe and can help reduce spleen size and symptoms in people with myelofibrosis and related myeloid conditions.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT07379125

• Considering allogeneic stem cell transplant using digital patient stories and values tools

  This program will test whether digital patient stories plus values-clarification exercises help adults with myeloid cancers who are deciding about allogeneic hematopoietic cell transplantation make choices that fit their goals.

  Recruiting University of Rochester · Rochester, New York · NCT07263074

• Germline testing for inherited risk of myeloid blood cancers

  This research will test whether a germline genetic test (MyeloGen Gene Panel) can find inherited changes linked to myeloid blood cancers in adults who have been diagnosed.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07112287

• Adding decitabine and venetoclax to fludarabine/melphalan reduced‑intensity transplant for myeloid cancers

  This study tests whether giving decitabine and venetoclax around a reduced‑intensity allogeneic transplant is safe for adults with high‑risk acute myeloid leukemia or myelodysplastic syndromes.

  Recruiting Phase 1 University of Alabama at Birmingham · Birmingham, Alabama · NCT07044544

• TQB3909 tablets combined with azacitidine for myeloid malignancies

  This trial tests whether taking oral TQB3909 together with azacitidine helps adults with myeloid malignancies respond better to treatment and tolerate therapy.

  Recruiting Phase 1/2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Bengbu, Anhui and 20 other locations · NCT07011186

• Combination treatment for relapsed or refractory acute myeloid leukemia

  This study is testing a new combination of three medications to see if it can help people with relapsed or refractory acute myeloid leukemia feel better and improve their treatment results.

  Recruiting Phase 2 First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT06621212

• GTB-3650 treatment for high-risk myeloid malignancies

  This study is testing a new treatment called GTB-3650 to see if it can help adults with tough-to-treat blood cancers like acute myeloid leukemia feel better and respond to therapy.

  Recruiting Phase 1 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT06594445

• Evaluating GLB-001 for patients with myeloid malignancies

  This study is testing a new oral treatment called GLB-001 to see if it is safe and effective for people with certain types of blood cancers that have come back or didn't respond to other treatments.

  Recruiting at 14 sites Phase 1 Hangzhou GluBio Pharmaceutical Co., Ltd. · Hefei, Anhui and 13 other locations · NCT06378437

• Low-dose decitabine plus venetoclax maintenance after allogeneic stem cell transplant

  This trial tests whether weekly low-dose decitabine followed 6–8 hours later by a venetoclax pill can help prevent relapse after allogeneic stem cell transplant in adults with AML or high‑risk MDS.

  Recruiting at 2 sites Phase 1/2 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT06129734

• Telehealth program for advance care planning in older adults with myeloid malignancies

  This study tests if a telehealth program that helps older adults with blood cancers talk about their serious illness and make healthcare plans can reduce their anxiety and improve communication with doctors.

  Recruiting University of Rochester · Rochester, New York · NCT05875805

• Treatment for patients with relapsed or refractory acute myeloid leukemia

  This study is testing a new treatment called APG-2575, both alone and with other drugs, to see if it can help people with relapsed or hard-to-treat acute myeloid leukemia.

  Recruiting at 10 sites Phase 1/2 Ascentage Pharma Group Inc. · Beijing, Beijing Municipality and 11 other locations · NCT04501120

• Using azacitidine to improve donor chimerism in patients with myeloid malignancies after stem cell transplant

  This study is testing if the drug azacitidine can help patients with acute myeloid leukemia or myelodysplastic syndromes maintain healthy donor cells after a stem cell transplant without causing new complications.

  Recruiting Phase 2 Henry Ford Health System · Detroit, Michigan · NCT03850418

• Testing genetic markers for early detection of myeloid cancers and bone marrow failure

  This study is testing if looking for specific genetic markers in blood and tissue samples can help find myeloid cancers and bone marrow issues earlier in people who show early signs but aren't diagnosed yet.

  Recruiting at 3 sites Mayo Clinic · Scottsdale, Arizona and 2 other locations · NCT02958462

NIH-funded research (4)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Myeloid Cancer Gene Variant Curation Expert Panel

  A patient-facing group creates and shares trusted rules for interpreting genetic variants that raise the risk of blood cancers, helping families understand their test results.

  NIH research Northwestern University · Chicago, United States · NIH-11384370

• Genetic variant review team for myeloid blood cancers

  Experts are reviewing inherited genetic changes that raise the risk of myeloid blood cancers so patients and families get clearer test results and care guidance.

  NIH research Northwestern University · Chicago, United States · NIH-11124044

• Creating a bone marrow model to study a genetic platelet disorder and its cancer risks

  This study is looking at a rare genetic condition that affects blood platelets and can increase the risk of blood cancers, and it's for people with this condition; the researchers want to create a mini version of bone marrow to better understand the disease and find new ways to help reduce the risk of leukemia.

  NIH research Boston Children's Hospital · Boston, United States · NIH-11011813

• Understanding genetic risks for blood cancers

  This study is looking at specific genetic changes that might make people more likely to develop certain blood cancers, and it aims to help patients and their families understand their risks better and find more personalized ways to manage their health.

  NIH research Northwestern University at Chicago · Chicago, United States · NIH-10887719

Related topics

Quick answers

How many Myeloid Malignancy clinical trials are recruiting right now?

14, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 4 countries. The most sites are in United States (9 trials), China (5 trials), Australia (1 trial), New Zealand (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 5, Phase 1/2: 3, Phase 2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →